BACKGROUND: Drug-induced pulmonary toxicity is a serious and expanding problem with often unknown aetiology. Many drugs are metabolized by cytochrome P450 (CYP) enzymes. OBJECTIVE: To establish whether allelic variation in CYP polymorphic genes contributes to variability in drug response and unexpected toxicity. METHODS: A case-control study was conducted. The cases consisted of patients with drug-induced interstitial lung disease (DI-ILD; n = 59). Two control groups were used: one group of healthy volunteers (n = 173) and one group of patients with idiopathic pulmonary fibrosis (IPF; n = 110). RESULTS: Of the patients with DI-ILD 91.5% (54/59) had at least one of the studied variant genes compared with 70.5% (122/173, p < 0.001) of the healthy volunteers and 69.1% (76/110, p < 0.001) of the IPF patients. The percentage of individuals with one or more variant CYP genes was higher in the DI-ILD group. Odds ratios were significantly increased and ranged from 3.25 to 40.8, indicating a significant association between the development of DI-ILD and the presence of one or more variant CYP genes. CONCLUSION: DI-ILD appeared to be associated with the presence of at least one variant CYP allele. This study supports the potential usefulness of personalized medicine by genotyping aiming to improve efficacy, tolerability and drug safety.
BACKGROUND: Drug-induced pulmonary toxicity is a serious and expanding problem with often unknown aetiology. Many drugs are metabolized by cytochrome P450 (CYP) enzymes. OBJECTIVE: To establish whether allelic variation in CYP polymorphic genes contributes to variability in drug response and unexpected toxicity. METHODS: A case-control study was conducted. The cases consisted of patients with drug-induced interstitial lung disease (DI-ILD; n = 59). Two control groups were used: one group of healthy volunteers (n = 173) and one group of patients with idiopathic pulmonary fibrosis (IPF; n = 110). RESULTS: Of the patients with DI-ILD 91.5% (54/59) had at least one of the studied variant genes compared with 70.5% (122/173, p < 0.001) of the healthy volunteers and 69.1% (76/110, p < 0.001) of the IPF patients. The percentage of individuals with one or more variant CYP genes was higher in the DI-ILD group. Odds ratios were significantly increased and ranged from 3.25 to 40.8, indicating a significant association between the development of DI-ILD and the presence of one or more variant CYP genes. CONCLUSION: DI-ILD appeared to be associated with the presence of at least one variant CYP allele. This study supports the potential usefulness of personalized medicine by genotyping aiming to improve efficacy, tolerability and drug safety.
Authors: Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann Journal: Drug Saf Date: 2006 Impact factor: 5.606
Authors: Ivana V Yang; Lauranell H Burch; Mark P Steele; Jordan D Savov; John W Hollingsworth; Erin McElvania-Tekippe; Katherine G Berman; Marcy C Speer; Thomas A Sporn; Kevin K Brown; Marvin I Schwarz; David A Schwartz Journal: Am J Respir Crit Care Med Date: 2006-09-22 Impact factor: 21.405
Authors: Petal A Wijnen; Catharina F Linssen; Guido R Haenen; Otto Bekers; Marjolein Drent Journal: Mol Diagn Ther Date: 2010-02-01 Impact factor: 4.074
Authors: Giulio Distefano; Luigi Fanzone; Monica Palermo; Francesco Tiralongo; Salvatore Cosentino; Corrado Inì; Federica Galioto; Ada Vancheri; Sebastiano E Torrisi; Letizia A Mauro; Pietro V Foti; Carlo Vancheri; Stefano Palmucci; Antonio Basile Journal: Diagnostics (Basel) Date: 2020-04-22
Authors: Sarah Skeoch; Nicholas Weatherley; Andrew J Swift; Alexander Oldroyd; Christopher Johns; Conal Hayton; Alessandro Giollo; James M Wild; John C Waterton; Maya Buch; Kim Linton; Ian N Bruce; Colm Leonard; Stephen Bianchi; Nazia Chaudhuri Journal: J Clin Med Date: 2018-10-15 Impact factor: 4.241
Authors: Naomi T Jessurun; Petal A Wijnen; Aalt Bast; Eugène P van Puijenbroek; Otto Bekers; Marjolein Drent Journal: Int J Mol Sci Date: 2020-04-16 Impact factor: 5.923